Tech Company Financing Transactions
Cellbricks Therapeutics Funding Round
On 3/25/2026, Cellbricks Therapeutics received $11.5 million in funding from private investors.
Transaction Overview
Company Name
Announced On
3/25/2026
Transaction Type
Venture Equity
Amount
$11,500,500
Round
Undisclosed
Investors
Proceeds Purpose
Funding will accelerate preclinical validation and enable Cellbricks Therapeutics to move from promise to proof, demonstrating that engineered human tissues can perform in clinically relevant models.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Müllerstraße 178
Berlin, 13353
Germany
Berlin, 13353
Germany
Phone
Email Address
Overview
Cellbricks Therapeutics is a Berlin and Boston-based preclinical biotech company pioneering the future of regenerative medicine and longevity. Built on deep tech innovation, the company combines proprietary biofabrication technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks' mission is to transform healthcare by restoring tissue function -- reliably and at scale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Troy Dale
Chief Executive Officer
Alexander Leutner
Chief Executive Officer
Simon MacKenzie
Chief Financial Officer
Michael Kring
Chief Medical Officer
Kathy Kordy
Chief Technical Officer
Tobias Lam
Browse more venture capital transactions:
Prev: 3/25/2026: Renasens venture capital transaction
Next: 3/25/2026: Centivax venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs